{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:54:25Z","timestamp":1791665665904,"version":"4.3.4"},"reference-count":104,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Chronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is per se a major risk factor for subsequent complications such as atherosclerosis, coronary heart disease, acute myocardial infarction, ischemic stroke, and nephropathy. Therefore, readjusting lipid metabolism in the diabetic milieu is a major goal for preventing dyslipidemia-induced complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of relatively newly introduced antidiabetes drugs (including empagliflozin, canagliflozin, dapagliflozin, etc.) with potent hypoglycemic effects and can reduce blood glucose by inducing glycosuria. However, recent evidence suggests that they could also provide extra-glycemic benefits in lipid metabolism. It seems that they can increase fat burning and lipolysis, normalizing the lipid metabolism and preventing or improving dyslipidemia. Nevertheless, the exact mechanisms involved in this process are not well-understood. In this review, we tried to explain how these drugs could regulate lipid homeostasis and we presented the possible involved cellular pathways supported by clinical evidence.<\/jats:p>","DOI":"10.3390\/jcm11216544","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T03:28:10Z","timestamp":1667532490000},"page":"6544","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu"],"prefix":"10.3390","volume":"11","author":[{"given":"Habib","family":"Yaribeygi","sequence":"first","affiliation":[{"name":"Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Maleki","sequence":"additional","affiliation":[{"name":"Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Center Zagreb, 1000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1444","authenticated-orcid":false,"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.15585\/mmwr.mm6906a3","article-title":"Trends in incidence of type 1 and type 2 diabetes among youths\u2014Selected counties and Indian reservations, United States, 2002\u20132015","volume":"69","author":"Divers","year":"2020","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s42000-018-0014-8","article-title":"Diabetes and lipid metabolism","volume":"17","author":"Athyros","year":"2018","journal-title":"Hormones"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/dme.13943","article-title":"Ceramides and diabetes mellitus: An update on the potential molecular relationships","volume":"37","author":"Yaribeygi","year":"2020","journal-title":"Diabet. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11154-019-09512-0","article-title":"Dietary lipids, gut microbiota and lipid metabolism","volume":"20","author":"Schoeler","year":"2019","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cjca.2017.12.029","article-title":"Abnormal myocardial dietary fatty acid metabolism and diabetic cardiomyopathy","volume":"34","author":"Carpentier","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Iacobini, C., Vitale, M., Pesce, C., Pugliese, G., and Menini, S. (2021). Diabetic complications and oxidative stress: A 20-year voyage back in time and back to the future. Antioxidants, 10.","DOI":"10.3390\/antiox10050727"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117090","DOI":"10.1016\/j.lfs.2019.117090","article-title":"Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review","volume":"240","author":"Yaribeygi","year":"2020","journal-title":"Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109526","DOI":"10.1016\/j.biopha.2019.109526","article-title":"The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update","volume":"120","author":"Yaribeygi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.dsx.2019.03.031","article-title":"Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes","volume":"13","author":"Yaribeygi","year":"2019","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1871530319666191014110414","article-title":"A review on the effects of new anti-diabetic drugs on platelet function","volume":"20","author":"Yaribeygi","year":"2020","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.7150\/thno.54498","article-title":"Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!","volume":"101","author":"Ranjbar","year":"2019","journal-title":"Metab. Clin. Exp."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104611","DOI":"10.1016\/j.phrs.2019.104611","article-title":"Neuromodulatory effects of anti-diabetes medications: A mechanistic review","volume":"152","author":"Yaribeygi","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Szekeres, Z., Toth, K., and Szabados, E. (2021). The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites, 11.","DOI":"10.3390\/metabo11020087"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium\u2013glucose cotransporter inhibitors and oxidative stress: An update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2014.10.2819","article-title":"Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes","volume":"126","author":"Davidson","year":"2014","journal-title":"Postgrad. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1139\/cjpp-2021-0399","article-title":"Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis","volume":"100","author":"Gronda","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1248\/bpb.b18-00728","article-title":"In vitro pharmacological profile of ipragliflozin, a sodium glucose co-transporter 2 Inhibitor","volume":"42","author":"Takasu","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: A new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin. Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014A novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metab. Clin. Exp."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12020-016-0943-4","article-title":"SGLT2 inhibitors in the management of type 2 diabetes","volume":"53","author":"Reddy","year":"2016","journal-title":"Endocrine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2337\/db20-0369","article-title":"The role of glucagon in the acute therapeutic effects of SGLT2 inhibition","volume":"69","author":"Lund","year":"2020","journal-title":"Diabetes"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Shyr, Z.A., Yan, Z., Ustione, A., Egan, E.M., and Remedi, M.S. (2022). SGLT2 inhibitors therapy protects glucotoxicity-induced \u03b2-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0258054"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrm3699","article-title":"The biophysics and cell biology of lipid droplets","volume":"14","author":"Thiam","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"a040576","DOI":"10.1101\/cshperspect.a040576","article-title":"Lipid metabolism","volume":"13","author":"Chandel","year":"2021","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_34","unstructured":"Hall, J.E., and Hall, M.E. (2020). Guyton and Hall Textbook of Medical Physiology e-Book, Elsevier Health Sciences."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1815178","DOI":"10.1155\/2021\/1815178","article-title":"The Impact of Incretin-Based Medications on Lipid Metabolism","volume":"2021","author":"Yaribeygi","year":"2021","journal-title":"J. Diabetes Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Aguilar-Ballester, M., Herrero-Cervera, A., Vinu\u00e9, \u00c1., Mart\u00ednez-Herv\u00e1s, S., and Gonz\u00e1lez-Navarro, H. (2020). Impact of cholesterol metabolism in immune cell function and atherosclerosis. Nutrients, 12.","DOI":"10.3390\/nu12072021"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-018-4732-x","article-title":"Dynamics of adipose tissue turnover in human metabolic health and disease","volume":"62","author":"White","year":"2019","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16987","DOI":"10.1002\/jcp.28420","article-title":"Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1002\/jcp.27603","article-title":"Insulin resistance: Review of the underlying molecular mechanisms","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1586\/17474124.2015.1056156","article-title":"Physiology and pathophysiology of liver lipid metabolism","volume":"9","author":"Ponziani","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41575-019-0250-7","article-title":"Regulation of intestinal lipid metabolism: Current concepts and relevance to disease","volume":"17","author":"Ko","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cisa-Wieczorek, S., and Hern\u00e1ndez-Alvarez, M.I. (2020). Deregulation of Lipid Homeostasis: A Fa (c) t in the Development of Metabolic Diseases. Cells, 9.","DOI":"10.3390\/cells9122605"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3389\/fphys.2020.01050","article-title":"Dyslipidemia in kidney disorders: Perspectives on mitochondria homeostasis and therapeutic opportunities","volume":"11","author":"Lin","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nishi, H., Higashihara, T., and Inagi, R. (2019). Lipotoxicity in kidney, heart, and skeletal muscle dysfunction. Nutrients, 11.","DOI":"10.3390\/nu11071664"},{"key":"ref_45","first-page":"778","article-title":"Lipid metabolism and carcinogenesis, cancer development","volume":"8","author":"Long","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s11427-019-1563-3","article-title":"Regulation of glucose and lipid metabolism in health and disease","volume":"62","author":"Chen","year":"2019","journal-title":"Sci. China Life Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Cuevas, J., Santos, A., and Armendariz-Borunda, J. (2021). Pathophysiological molecular mechanisms of obesity: A link between MAFLD and NASH with cardiovascular diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111629"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Cuevas, J., Sandoval-Rodriguez, A., Meza-Rios, A., Monroy-Ram\u00edrez, H.C., Galicia-Moreno, M., Garc\u00eda-Ba\u00f1uelos, J., Santos, A., and Armendariz-Borunda, J. (2021). Molecular mechanisms of obesity-linked cardiac dysfunction: An up-date on current knowledge. Cells, 10.","DOI":"10.3390\/cells10030629"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.22881","article-title":"Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk","volume":"41","author":"Taraszkiewicz","year":"2018","journal-title":"Clin. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Penno, G., Solini, A., Zoppini, G., Fondelli, C., Trevisan, R., Vedovato, M., Gruden, G., Lamacchia, O., Pontiroli, A.E., and Arosio, M. (2015). Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with type 2 diabetes: A cross-sectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125512"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e12283","DOI":"10.1097\/MD.0000000000012283","article-title":"Relationship between dyslipidemia and diabetic retinopathy: A systematic review and meta-analysis","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.oret.2017.05.010","article-title":"Diabetic retinopathy in patients with dyslipidemia: Development and progression","volume":"2","author":"Jeng","year":"2018","journal-title":"Ophthalmol. Retin."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.2147\/DMSO.S283171","article-title":"Dyslipidemia and its associated risk factors among adult type-2 diabetic patients at Jimma University Medical Center, Jimma, Southwest Ethiopia","volume":"13","author":"Haile","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MED.0000000000000533","article-title":"The emerging role of dyslipidemia in diabetic microvascular complications","volume":"27","author":"Savelieff","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/0976-9668.149117","article-title":"Association of atherosclerosis with dyslipidemia and co-morbid conditions: A descriptive study","volume":"6","author":"Garg","year":"2015","journal-title":"J. Nat. Sci. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/CIRCRESAHA.108.178533","article-title":"Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme a desaturase","volume":"103","author":"Savransky","year":"2008","journal-title":"Circ. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3164\/jcbn.2008044","article-title":"Increasing oxidative stress with progressive hyperlipidemia in human: Relation between malondialdehyde and atherogenic index","volume":"43","author":"Yang","year":"2008","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1172\/JCI61462","article-title":"Regulation of lipogenesis by cyclin-dependent kinase 8\u2013mediated control of SREBP-1","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.chemphyslip.2011.06.004","article-title":"Liver X Receptor: An oxysterol sensor and a major player in the control of lipogenesis","volume":"164","author":"Ducheix","year":"2011","journal-title":"Chem. Phys. Lipids"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrm4074","article-title":"Transcriptional regulation of hepatic lipogenesis","volume":"16","author":"Wang","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Song, Z., Xiaoli, A.M., and Yang, F. (2018). Regulation and metabolic significance of de novo lipogenesis in adipose tissues. Nutrients, 10.","DOI":"10.3390\/nu10101383"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fnmol.2018.00010","article-title":"Neuronal lipid metabolism: Multiple pathways driving functional outcomes in health and disease","volume":"11","author":"Tracey","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biocel.2009.12.009","article-title":"Lipolysis in adipocytes","volume":"42","author":"Ahmadian","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00125-016-3896-5","article-title":"GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1","volume":"59","author":"Xu","year":"2016","journal-title":"Diabetologia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.nutr.27.061406.093734","article-title":"Regulation of lipolysis in adipocytes","volume":"27","author":"Duncan","year":"2007","journal-title":"Annu. Rev. Nutr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e210558","DOI":"10.1530\/EC-21-0558","article-title":"Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes","volume":"11","author":"Lauritsen","year":"2022","journal-title":"Endocr. Connect."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1042\/BCJ20200278","article-title":"The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice","volume":"477","author":"Day","year":"2020","journal-title":"Biochem. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","article-title":"Cholesterol metabolism and homeostasis in the brain","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/10409238.2021.1925217","article-title":"Cholesterol efflux pathways, inflammation, and atherosclerosis","volume":"56","author":"Groenen","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: A randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","first-page":"76","article-title":"Effects of dapagliflozin on serum low-density lipoprotein cholesterol and triglyceride levels","volume":"26","year":"2020","journal-title":"Eur. J. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"15449","DOI":"10.1038\/s41598-022-19371-6","article-title":"Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure","volume":"12","author":"Ejiri","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1179551419866811","DOI":"10.1177\/1179551419866811","article-title":"Potential impact on lipoprotein subfractions in type 2 diabetes","volume":"12","author":"Kamijo","year":"2019","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/dom.14452","article-title":"High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials","volume":"23","author":"Shi","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12944-017-0443-4","article-title":"A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes","volume":"16","author":"Cha","year":"2017","journal-title":"Lipids Health Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canlet.2018.08.006","article-title":"Fatty acid oxidation: An emerging facet of metabolic transformation in cancer","volume":"435","author":"Ma","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.peptides.2017.12.005","article-title":"Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism","volume":"100","author":"Almutairi","year":"2018","journal-title":"Peptides"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1038\/s41598-019-46594-x","article-title":"SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait","volume":"9","author":"Wu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100176","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"J. Lipid Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2337\/db20-0921","article-title":"SGLT2 inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: A randomized double-blind, placebo-controlled crossover trial","volume":"70","author":"Lauritsen","year":"2021","journal-title":"Diabetes"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc21-2043","article-title":"The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes","volume":"45","author":"Herring","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2337\/db19-1881-P","article-title":"1881-P: The SGLT2 Inhibitor Dapagliflozin Improves Glucose Control and Enhances Liver Fatty Acid Oxidation and Ketone Body Formation in Insulin Resistant Obese Zucker Rats","volume":"68","author":"Kroon","year":"2019","journal-title":"Diabetes"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"165-LB","DOI":"10.2337\/db19-165-LB","article-title":"165-LB: The SGLT2 Inhibitor Canagliflozin Prevents Increased Lipid Oxidation in the Heart following High-Fat Feeding","volume":"68","author":"Flores","year":"2019","journal-title":"Diabetes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1432-1033.2003.03947.x","article-title":"Mitochondrial \u03b2-oxidation","volume":"271","author":"Bartlett","year":"2004","journal-title":"Eur. J. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"360438","DOI":"10.1155\/2014\/360438","article-title":"Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal","volume":"2014","author":"Ayala","year":"2014","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"108941","DOI":"10.1016\/j.abb.2021.108941","article-title":"Lipid peroxidation as measured by chromatographic determination of malondialdehyde. Human plasma reference values in health and disease","volume":"709","author":"Dromant","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","article-title":"Lipid peroxidation and ferroptosis: The role of GSH and GPx4","volume":"152","author":"Ursini","year":"2020","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0027-5107(99)00010-X","article-title":"Lipid peroxidation\u2014DNA damage by malondialdehyde","volume":"424","author":"Marnett","year":"1999","journal-title":"Mutat. Res. Fundam. Mol. Mech. Mutagen."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/jp.2014.45","article-title":"Lipid peroxidation, DNA damage and total antioxidant status in neonatal hyperbilirubinemia","volume":"34","author":"Basu","year":"2014","journal-title":"J. Perinatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fphar.2021.708177","article-title":"A SGLT2 Inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro","volume":"12","author":"Xing","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/jdi.13009","article-title":"Canagliflozin, an SGLT2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats","volume":"10","author":"Kimura","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/jpet.118.253666","article-title":"Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats","volume":"368","author":"Oshima","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S1106","DOI":"10.1016\/j.annonc.2020.08.1361","article-title":"1969P The SGLT2 inhibitor dapagliflozin enhanced anticancer activities and exerts cardioprotective effects against doxorubicin and trastuzumab toxicity through TLR4, MyD88, NF-kB signaling and NLRP3 inflammasome pathway","volume":"31","author":"Maurea","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_101","first-page":"111","article-title":"Lipids: Absorption and transport","volume":"1","author":"Lichtenstein","year":"2012","journal-title":"Present Knowl. Nutr."},{"key":"ref_102","unstructured":"Feingold, K.R., and Grunfeld, C. (2015). Introduction to Lipids and Lipoproteins, MDText.com, Inc."},{"key":"ref_103","unstructured":"Arvind, A., Osganian, S.A., Cohen, D.E., and Corey, K.E. (2019). Lipid and Lipoprotein Metabolism in Liver Disease, MDText.com, Inc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.freeradbiomed.2020.11.011","article-title":"Up-regulation of thioredoxin system by puerarin inhibits lipid uptake in macrophages","volume":"162","author":"Li","year":"2021","journal-title":"Free Radic. Biol. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6544\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:10:26Z","timestamp":1760145026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":104,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11216544"],"URL":"https:\/\/doi.org\/10.3390\/jcm11216544","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]}}}